[1]查林,冯世斌,李前伟.非霍奇金淋巴瘤的CD20分子显像及靶向治疗研究进展[J].国际放射医学核医学杂志,2010,34(5):269-273.[doi:10.3760/cma.j.issn.1673-4114.2010.05.004]
　ZHA Lin,FENG Shi-bin,LI Qian-wei.Progress of study on the molecular imaging and targeted therapy in CD20 of non Hodgkin’s lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(5):269-273.[doi:10.3760/cma.j.issn.1673-4114.2010.05.004]
点击复制

非霍奇金淋巴瘤的CD20分子显像及靶向治疗研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
34
期数:
2010年第5期
页码:
269-273
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Progress of study on the molecular imaging and targeted therapy in CD20 of non Hodgkin’s lymphoma
作者:
查林;  冯世斌;  李前伟
400038, 重庆第三军医大学西南医院核医学科
Author(s):
ZHA Lin;  FENG Shi-bin;  LI Qian-wei
Department of Nuclear Medicine, Southwest Hospital of the Third Military Medical University, Chongqing 400038, China
关键词:
非霍奇金淋巴瘤; CD20; 利妥昔单抗; 免疫治疗; 放射免疫显像
Keywords:
Non-Hodgkin’s lymphoma; Cluster of differentiation 20; Rituximab; Immunotherapy; Radioimmunoimaging
DOI:
10.3760/cma.j.issn.1673-4114.2010.05.004
摘要:
应用放射性核素标记B淋巴细胞分化抗原CD20单抗或其重组片段,在分子水平实现对非霍奇金淋巴瘤(NHL)显像和治疗,这将成为提高患者生存率的有效手段。该文介绍了CD20表面抗原的生物学特性及NHL抗CD20单抗的免疫治疗、放射免疫治疗以及放射免疫显像的研究进展。
Abstract:
The molecular imaging and targeted therapy with radiolabeled anti-CD20 monoclonal antibody or recombinant anti-CD20 monoclonal antibody fragments is the effective methods to improve the survival rate for non-Hodgkin’s lymphoma (NHL). This article reviews the biological characteristics of CD20 and the immunotherapy, radioimmunotherapy, radioimmunoimaging with anti-CD20 monoclonal antibody for NHL.

参考文献/References:

[1] 任金马,蓝绍颖.恶性淋巴瘤的流行病学研究进展.南通医学院学报,2003,23(4):523-524.
[2] 刘银星,杨纯正.CD20分子与靶向治疗.生命的化学,2003,23(1):60-62.
[3] Du J, Wang H, Zhong C, et al. Structural basis for recognition of CD20 by therapeutic antibody rimximab. J Biol Chem, 2007, 282(20):15073-15080.
[4] Jacobs SA, Foon KA. The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas. Expert Opin Biol Ther, 2007, 7(1 l):1749-1762.
[5] Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis, 2002, 61(10):922-924.
[6] 李禹兵,刘延香,路喻清.非霍奇金淋巴瘤的研究进展.现代肿瘤医学,2010,18(3):620-624.
[7] Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoelonal antibody ritttximab. Ann Oncol, 2003, 14(4):520-535.
[8] Du J, Wang H, Zhong C, et al. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. Mol Immunol, 2008, 45(10):2861-2868.
[9] Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies, Mol Immunol, 2007, 44(16):3823-3837.
[10] Goldblatt F, Iseuberg DA. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus. Handb Exp Pharmacol, 2008,181:163-181.
[11] Hayden-Ledbetter MS, Cerveny CG, Espling E, et al. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res, 2009, 15(8):2739-2746.
[12] Rossi EA, Goldenberg DM, Cardillo TM, et al. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res, 2008, 68(20):8384-8392.
[13] Leahy MF, Seymour JF, Hicks RJ, et al. Multicenter phase Ⅱ clinical study of iodine-131-rituximab radioimmnnotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol, 2006, 24(27):4418-4425.
[14] Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibrltumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma:a phase Ⅱ trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma, 2009, 9(3):223-228.
[15] Forrer F, Chen J, Fani M, et al. In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med and Mol Imaging, 2009, 36(9):1443-1452.
[16] Beyer GJ, Miederer M, Vranjes-Duri? S, et al. Targeted alpha therapy in vivo:direct evidence for single cancer cell kill using 149Tb-rituximab. Eur J Nucl Med Mol hnaging, 2004, 31(4):547-554.
[17] Cronin CG, Swords R, Truong MT, et al. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol, 2010, 194(1):W91-W103.
[18] Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med, 2009, 50(Suppl 1):21S-30S.
[19] Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program, 2006, 501(1):259-265.
[20] Kazama T, Faria SC, Varavithya V, et al, FDG PET in the evaluation of treatment for lymphoma:clinical usefulness and pitfalls. Radiographics, 2005, 25(1):191-207.
[21] Stopar TG, Mlinmric-Rascan I, Fettich J, et al. 99mTc-rituximab radiolabelled by photo-activation:a new non-Hodgkin’s lymphoma imaging agent. Eur J Nucl Med Mol Imaging. 2006, 33(1):53-59.
[22] Gmeiner Stopar T, Fettich J, Zver S, et al. 99mTc-labelled rituximab, a new non-Hodgkin’s lymphonaa imaging agent:first clinical experience. Nucl Med Commun, 2008, 29(12):1059-1065.
[23] Olafsen T, Betting D, Kenanova VE, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med, 2009, 50(9):1500-1508.
[24] Olafsen T, Sirk SJ, Betting DJ, et al. ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 seFv dimers (diabodies). Protein Eng, Des Sel, 2010, 23(4):243-249.

相似文献/References:

[1]蔡秋琼,杜明华.131Ⅰ-rituximab治疗B细胞非霍奇金淋巴瘤[J].国际放射医学核医学杂志,2008,32(2):72.
　CAI Qiu-qiong,DU Ming-hua.131Ⅰ-rituximab therapy of B cell non-Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(5):72.
[2]魏莉,罗荣城.放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展[J].国际放射医学核医学杂志,2006,30(3):153.
　WEI Li,LUO Rong-cheng.Advances in research of radioactive nuclide labeled anti-CD20 monoclonal antibody in B cell lymphomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(5):153.
[3]陈立波,朱瑞森.Bexxar治疗非霍奇金淋巴瘤的研究现状[J].国际放射医学核医学杂志,2005,29(2):67.
　CHEN Li-bo,ZHU Rui-sen.Current status of Bexxar for treatment of non-Hodgkin’s lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):67.
[4]张晶洁,张万春,李晓敏,等.新型特异性靶向前哨淋巴结示踪剂的研究进展[J].国际放射医学核医学杂志,2018,(1):69.[doi:10.3760/cma.j.issn.1673-4114.2018.01.013]
　Zhang Jingjie,Zhang Wanchun,Li Xiaomin,et al.Research progress in the new specific receptor-targeted sentinel lymph node agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):69.[doi:10.3760/cma.j.issn.1673-4114.2018.01.013]

备注/Memo

备注/Memo:
收稿日期:2010-02-11。
通讯作者:李前伟,E-mail:tmmuxnyy@yahoo.com.cn
更新日期/Last Update: 1900-01-01